Pfizer Inc. (PFE) Earnings Call Transcripts
Pfizer Inc.'s Latest Earnings Call - June 8, 2026
In the Q1 2026 earnings call, Pfizer Inc. (PFE:US) reported strong performance despite a significant decline in COVID-related revenues. The company achieved revenues of $16.5 billion, surpassing expectations of $15.0 billion, and delivered an EPS of $2.45, beating the consensus estimate of $2.30. Management maintained a cautious outlook on COVID revenues, guiding for $5 billion in 2026, while expressing confidence in a diversified portfolio that includes promising oncology and obesity treatments. The company anticipates a high single-digit revenue CAGR starting in 2029, driven by a robust pipeline and successful product launches.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $16.5B (beat) |
| EPS | $2.45 (beat) |
| COVID Revenue Guidance | $5B (negative) |
| Revenue Growth in Oncology | 22% (positive) |
| M&A Capacity | $7B (neutral) |
| Long-term Revenue CAGR | High single digits (positive) |
Guidance from management
Pfizer maintained its COVID revenue guidance at $5 billion for 2026, while expressing confidence in achieving high single-digit revenue CAGR starting in 2029, driven by a strong pipeline and successful product launches.
What management said
Actually, that's the efficiency and the cost reduction because of AI, it is the least valuable thing. It's going to be significant, but it's the least valuable thing. I think the commercial model is changing dramatically with AI. So you can gain significant market share if you know how to deal with the big models. Physicians are getting all their information from LLMs. So things will change dramatically. So if you ...
You need options because the market is having different segments. So the very high weight loss, it is for those that only need, which is the very high BMI is not for the masses, right? For the masses, they want something that is comparable to 15% to 20%, 20%, 20 plus, which is the current offerings from semaglutide to tirzepatide, but we believe that they want it in a convenient way, which is coming now. Also, yo...
What analysts pressed on
Analysts expressed concerns regarding the uncertainty surrounding COVID treatment revenues and the potential impact of emerging competition from China. There were questions about how Pfizer plans to navigate these challenges while maintaining growth in its core business segments.
Main topics on the call
- Strong Revenue Performance — Pfizer reported Q1 2026 revenues of $16.5 billion, exceeding expectations of $15.0 billion. CEO Albert Bourla stated, "we beat the expectations of revenues or EPS" consistently over the past quarters, highlighting the co...
- Pipeline Developments in Oncology — Management emphasized the oncology pipeline as a key growth driver, particularly with lornatinib for thoracic cancer and promising data for other cancer treatments. Bourla noted, "the crown jewel of our R&D business righ...
- COVID Revenue Guidance — Pfizer guided for $5 billion in COVID-related revenues for 2026, down from $6.5 billion in 2025. Bourla expressed caution, stating, "I want to see how COVID will evolve," reflecting uncertainty around future COVID treatm...
- AI Integration and Cost Reductions — The company is leveraging AI for significant cost reductions, with Bourla stating, "we didn't just cut but we transform productivity to the next level." This strategic focus on AI is expected to enhance operational effic...
Read the full Pfizer Inc. transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Pfizer Inc.
Pfizer Inc. (PFE) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 113 calls on record spanning January 14, 2020 to June 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 113 Pfizer Inc. earnings call transcripts on record, spanning January 14, 2020 to June 8, 2026. Based on this history, Pfizer Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PFE
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 113
- First call
- January 14, 2020
- Most recent
- June 8, 2026
- Reporting cadence
- quarterly